- Home
- CHH vs INDV Comparison
CHH vs INDV Comparison
Compare CHH & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHH | INDV |
|---|---|---|
| Founded | 1939 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.4B |
| IPO Year | 1997 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CHH | INDV |
|---|---|---|
| Price | $109.92 | $40.43 |
| Analyst Decision | Hold | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $114.30 | N/A |
| AVG Volume (30 Days) | 599.9K | ★ 1.7M |
| Earning Date | 04-30-2026 | 06-08-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | 27.42 | ★ 8100.00 |
| EPS | 0.44 | ★ 0.69 |
| Revenue | ★ $1,596,793,000.00 | $1,239,000,000.00 |
| Revenue This Year | $66.74 | N/A |
| Revenue Next Year | $0.37 | N/A |
| P/E Ratio | $249.25 | ★ $58.70 |
| Revenue Growth | 0.75 | ★ 4.29 |
| 52 Week Low | $84.04 | $15.00 |
| 52 Week High | $136.45 | $42.81 |
Technical Indicators
Market Signals| Indicator | CHH | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 57.41 |
| Support Level | $103.40 | $35.36 |
| Resistance Level | $110.35 | $41.00 |
| Average True Range (ATR) | 3.93 | 1.56 |
| MACD | -0.31 | -0.06 |
| Stochastic Oscillator | 51.72 | 55.32 |
Price Performance
Historical ComparisonAbout CHH Choice Hotels International Inc.
At year-end 2025, Choice Hotels operated 657,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total rooms), while Ascend and Cambria (10%) are lifestyle and select-service brands, and WoodSpring (5%) is the company's largest extended-stay brand. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2025.
About INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).